Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
Date de publication/diffusion :
2023
Titre du périodique :
Journal of Clinical Oncology
ISSN :
0732-183X
eISSN :
1527-7755
Maison d'édition :
Lippincott Williams & Wilkins, Etats-Unis
Volume/Tome :
41
Pagination :
327 - 335
Peer reviewed :
Peer reviewed vérifié par ORBi
Subventionnement (détails) :
We thank the patients, their families, and the LYSA, FIL, and EORTC investigators. Furthermore, we thank the BREACH study team of LYSARC. We thank loïc Chartier and Patrick Fogarty for statistical analysis. Medical editorial support was provided by Peter Todd of Tajut Ltd (Kaiapoi, New Zealand) and was funded by CHU UCL Namur, Yvoir, Belgium.Funding for this research was provided by Takeda Pharmaceuticals.
Fermé C, Eghbali H, Meerwaldt JH, et al: Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 357: 1916-1927, 2007
Noordijk EM, Carde P, Dupouy N, et al: Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: Long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 24: 3128-3135, 2006
Gillessen S, Plütschow A, Fuchs M, et al: Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: Long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14). Lancet Haematol 8: e278-e288, 2021
Hutchings M, Mikhaeel NG, Fields PA, et al: Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 16: 1160-1168, 2005
Gallamini A, Rigacci L, Merli F, et al: The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 91: 475-481, 2006
Hutchings M, Loft A, Hansen M, et al: FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107: 52-59, 2006
Radford J, Illidge T, Counsell N, et al: Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med 372: 1598-1607, 2015
André MPE, Girinsky T, Federico M, et al: Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: Final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 35: 1786-1794, 2017
Meignan M, Gallamini A, Meignan M, et al: Report on the first International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma 50: 1257-1260, 2009
Cottereau AS, Versari A, Loft A, et al: Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood 131: 1456-1463, 2018
Kanoun S, Rossi C, Berriolo-Riedinger A, et al: Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 41: 1735-1743, 2014
Moskowitz AJ, Schöder H, Gavane S, et al: Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood 130: 2196-2203, 2017
Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A,: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363: 1812-1821, 2010
Chen R, Gopal AK, Smith SE, et al: Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 128: 1562-1566, 2016
Moskowitz CH, Nademanee A, Masszi T, et al: Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 385: 1853-1862, 2015
Younes A, Connors JM, Park SI, et al: Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: A phase 1, open-label, dose-escalation study. Lancet Oncol 14: 1348-1356, 2013
Connors JM, Ansell SM, Fanale M, et al: Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma. Blood 130: 1375-1377, 2017
Connors JM, Jurczak W, Straus DJ, et al: Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med 378: 331-344, 2018
Specht L, Yahalom J, Illidge T, et al: Modern radiation therapy for Hodgkin lymphoma: Field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Intl J Radiat Oncol Biol Phys 89: 854-862, 2014
Juweid ME, Stroobants S, Hoekstra OS, et al: Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25: 571-578, 2007
Meignan M, Cottereau AS, Versari A, et al: Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: A pooled analysis of three multicenter studies. J Clin Oncol 34: 3618-3626, 2016
Mikhaeel NG, Smith D, Dunn JT, et al: Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging 43: 1209-1219, 2016
Cottereau AS, Hapdey S, Chartier L, et al: Baseline total metabolic tumor volume measured with fixed or different adaptive thresholding methods equally predicts outcome in peripheral T cell lymphoma. J Nucl Med 58: 276-281, 2017
Kumar A, Casulo C, Advani RH, et al: Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma. J Clin Oncol 39: 2257-2265, 2021
Abramson JS, Arnason JE, LaCasce AS, et al: Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma. Blood 134: 606-613, 2019
Kanoun S, Tal I, Berriolo-Riedinger A, et al: Influence of software tool and methodological aspects of total metabolic tumor volume calculation on baseline [18F]FDG PET to predict survival in Hodgkin lymphoma. PLoS One 10: e0140830, 2015
Tylski P, Stute S, Grotus N, et al: Comparative assessment of methods for estimating tumor volume and standardized uptake value in (18)F-FDG PET. J Nucl Med 51: 268-276, 2010
Borchmann P, Plütschow A, Kobe C, et al: PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 22: 223-234, 2021
Evens AM, Advani RH, Helenowski IB, et al: Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. J Clin Oncol 36: 3015-3022, 2018
Bröckelmann PJ, Goergen H, Keller U, et al: Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: The randomized phase 2 German Hodgkin Study Group NIVAHL trial. JAMA Oncol 6: 872-880, 2020
